Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 15/20 | 0.37 |
| ▸ | HTR2A | P28223 | 12/20 | 0.37 |
| ▸ | HTR2B | P41595 | 11/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6195483 | 0.84 | ALDH1A1 (0.40) | ALDH1A1GLAHTR2CHTR2AHTR2B | |
| SCHEMBL23552017 | 0.79 | TDP1 (0.36) | ALDH1A1GLAHTR2CHTR2AHTR2B | |
| SCHEMBL6975228 | 0.75 | ALDH1A1 (0.41) | ALDH1A1GLAHTR2ATDP1TP53 | |
| SCHEMBL6975232 | 0.75 | ALDH1A1 (0.41) | ALDH1A1GLAHTR2ATDP1TP53 | |
| SCHEMBL6309690 | 0.74 | ALDH1A1 (0.53) | ALDH1A1GLAHTR2CHTR2AHTR2B | |
| SCHEMBL6309685 | 0.74 | ALDH1A1 (0.53) | ALDH1A1GLAHTR2CHTR2AHTR2B | |
| SCHEMBL7966131 | 0.74 | ALDH1A1 (0.53) | ALDH1A1GLAHTR2CHTR2AHTR2B | |
| SCHEMBL6985499 | 0.72 | ALDH1A1 (0.48) | ALDH1A1GLATDP1TP53CYP3A4 | |
| SCHEMBL6985498 | 0.72 | ALDH1A1 (0.48) | ALDH1A1GLATDP1TP53CYP3A4 | |
| SCHEMBL6978043 | 0.72 | ALDH1A1 (0.48) | ALDH1A1GLATDP1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6353002-B2 | DIOXINOINDOLE AND THIENOBENZODIOXIN COMPOUNDS WHICH ARE HT3 RECEPTOR ANTAGONISTS AND ARE USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2002-03-05 | — | — | US | disclosed |
| US-20010008903-A1 | Therapeutic agents | BIRCH ALAN MARTIN (GB) | 2001-07-19 | — | — | US | disclosed |
| US-6201004-B1 | CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, CARDIOVASCULAR, BRAIN, AND GASTROINTESTINAL DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010008903-A1 | Therapeutic agents | GPR119, SNCA, HTR2B | ALDH1A1 3243/4885GLA 601/4885HTR2C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.